Johnson & Johnson Stock Price | JNJ Shares Chart

Johnson & Johnson Stock Price | JNJ Shares ChartCentral Index Key (CIK): 0000200406 | ISIN: US4781601046 | Symbol: JNJ | Type: Stock.
Johnson & Johnson is a US company famous for its sanitary and hygiene products. Nevertheless, the holding's main income comes from a completely different activity - J&J is one of the largest suppliers of medical equipment in the world (1st place in 2019 and 2nd place in 2020 according to Forbes). Johnson & Johnson shares are included in the Dow Jones Titans 50 index. The main trading takes place on the NYSE. Johnson & Johnson (JNJ) stock price today, live price online, charts, professional analytics, technical and fundamental analysis, comments, reports, dividends and more about Johnson & Johnson stocks.


Simple and lightweight Johnson & Johnson Stock Live Chart is a powerful free tool that allows you to easily conduct technical analysis online without downloading additional files and applications. In order to meet the needs of the most demanding technical analysts, you can find over a hundred chart analysis tools on our Johnson & Johnson stock chart. You can also add any of 80 technical indicators directly to the chart online - in two clicks. The possibilities are endless!

Technical Analysis Johnson & Johnson Stock


Johnson & Johnson Stocks Technical Analysis widget is a modern handy tool that shows ratings based on technical indicators data. The design of the widget is made in the form of a speedometer, thanks to which you can quickly see the results of the summary technical analysis. You no longer need to use many indicators for analyzing financial instruments, the widget will do it for you. In addition, all rating data are updated in real time. These technical indicators are used for technical analysis: Relative Strength Index, Stochastic, Commodity Channel Index, Average Directional Index, Awesome Oscillator, Momentum, MACD, Stochastic RSI, Williams Percent Range, Bull Bear Power, Ultimate Oscillator, Exponential Moving Average, Simple Moving Average, Ichimoku Cloud Base Line, Volume Weighted Moving Average, Hull Moving Average.

Fundamental Analysis Johnson & Johnson Stock


The widget displays fundamental data that will help you better understand the current state of the company than simple stock prices. Johnson & Johnson stock fundamentals include: Market Capitalization, Enterprise Value, Balance Sheet, Operating Metrics, Price History, Margins, Income Statement, Dividends and many others important data.

About Johnson & Johnson

At the moment J&J is one of the 10 largest US companies in terms of capitalization. Analysts call JNJ shares the most resilient in the sector. For the second world crisis in a row, stock prices fell by less than 25% and quickly recover by the end of the year.

Johnson & Johnson has 250 subsidiaries, the activities of which are distributed in three areas:

  • consumer goods;
  • pharmaceuticals;
  • medical equipment.

Johnson & Johnson owns several dozen brands, including Johnson's Baby hygiene line for children, Clean & Clear and Neutrogena cosmetics, Acuvue contact lenses. J&J products are sold in 175 countries around the world.

In 1886, the world first thought about the sterilization of surgical operations. At the same time, the three Johnson brothers decided to participate in the medical revolution and founded Johnson & Johnson, a company that, with only 14 employees, was the first to produce sterile dressings and doctor's gowns. Soon the company published a book, which for a long time was the only antiseptic manual. The result is a significant reduction in mortality during operations and the first step towards fame.

A Brief History of Johnson & Johnson Stocks from Simple-Invest

1888 - release of the world's first first aid kit.

1892 - the development of the legendary baby powder and the birth of the Johnson's Baby brand, with which the company is still associated with most consumers.

1900 - medical aid to the victims of the hurricane in Texas. Since then, charity has become a tradition of the company and regularly reflects on its reputation, and at the same time the trust of investors.

1919 - the first overseas subsidiary in Canada.

1921 - development of a bactericidal patch.

1924 - opening of an office in Great Britain.

1954 - Launch of the world's first tear-free baby shampoo. For six months, the novelty captured 75% of the niche market and firmly held its position for 40 years - until 1995.

1960s - a decline in sales as a result of tightening US government control in the healthcare sector.

1978 - Purchase of o.b., a German company for the production of feminine hygiene products.

1982 - 7 deaths from Tylenol, a pain reliever from J&J that was found to contain cyanide. The company urgently took a wide range of measures that made it possible to somewhat rehabilitate its reputation: withdrew the medicine from pharmacies, warned people about the danger, introduced a new package for medicines with a special insert to control the first opening.

1987 Johnson & Johnson became the general sponsor of the World Child Safety Program. Over 20 years, the measures taken have helped to reduce the number of child deaths due to trauma by 45%.

1990s - a number of major purchases, in particular RoC, Neutrogena, Eastman Kodak Company. This increased revenue by 53% over the next 3 years.

1997 - closure of 36 branches and reduction of 4100 employees. The measures were taken to save the budget for the sake of investment in research and development. Despite the decrease in resources, the year brought a record $ 27 billion in revenue - and this is 3 times more than in 1987.

2000 - death of patients from Propulsid. The company recalled a product that brought in about $ 1 billion.

2006 - acquisition of the Pfizer division.

2010 - seizure of McNeil products and plant closure due to inadequate quality, a series of lawsuits for illegal advertising. The company has paid nearly $ 2 billion in fines.

2011 - Payment of $ 70 million in compensation for bribes to doctors in several countries.

2013 - $ 2.5 billion in fines to the US authorities for illegal advertising.

2016 - Acquisition of the ophthalmic company Abbott Laboratories. Due to pharmaceuticals, profit increased by 7%.

2017 - decrease in net profit by 13 times due to tax reform, as a result of which the company had to pay a one-time $ 13.6 billion. At the same time, revenue indicators showed stable growth. A number of claims and millions of compensation due to the development of oncology as a result of the use of J&J products.

2018 - stable revenue growth, mainly due to sales of medical equipment; Acquisition of Japanese cosmetics brand Ci: z Holdings, supplier of vertebral implants EIT, developer of cloud service for evaluating the work of C-SATS surgeons and robotic technology for orthopedic surgery Orthotaxy.

2019 - buyout from Google of the developer of robotic surgeons Verb Surgical; tens of thousands of claims for defective products. A large number of legal claims negatively affected investor confidence and increased the total amount of expenses - according to analysts, the company spends annually on legal costs up to $ 50 billion.This led to a drop in quotations by 12% compared to December 2018.

2020 - Purchase of Momenta Pharmaceuticals, a developer of innovative treatments for immune diseases; development of an experimental vaccine against Covid-19.

2021 began with a string of failures. A number of states have alternately refused the vaccine, and the court ordered the payment of a $ 230 million fine for the harmful effects of opium-based painkillers. JNJ shares fell somewhat in price, but nevertheless, they continued to grow steadily in April. As of July 1, their cost is $ 165.9, which is $ 25 more than a year ago.

What is Important for an Investor to Know?

According to the results of the first quarter of 2021, Johnson & Johnson's net profit increased by 6.9%, compared to last year's indicators, and amounted to $ 6.2 billion. Earnings per share amounted to $ 2.32 against $ 2.15 a year earlier. Revenue was $ 22.3 billion, in line with analysts' expectations.

According to forecasts for 2021, the company should reach $ 90.6-91.6 billion in revenue. Earnings per share are projected to be $ 9.4-9.57 by the end of the year.

As you can see from the Johnson & Johnson story, the following factors can affect stock prices:

  • takeovers and sales of companies;
  • financial indicators;
  • state reforms in the field of taxation and health care;
  • external and internal economic situation;
  • scandals and lawsuits directly related to the company;
  • charity events.

For shareholders in whose investment portfolio there are J&J securities, it is rational to monitor the activities of both the company itself and its competitors. In the field of medical devices, these are Medtronic, Stryker, Becton Dickinson.

Over the past 5 years, the company's securities have shown stable growth, with the exception of the crisis in March 2020. However, the movement of the chart is cyclical. Analysts recommend not staying in anticipation of the upcoming growth, but making money on J&J shares right now.

Have Questions?

If you have any questions, then use the comments - and we will answer 100%, the average response time is 24 hours. Please note that your comments are pre-checked by the site administrators - therefore, your comment on the site will be published over time.

Comments

Johnson & Johnson Stock Forecast & Price Targets

Based on 6 Wall Street analysts offering 12 month price targets for Johnson & Johnson in the last 3 months.

The average price target is $188.60 with a high forecast of $200.00 and a low forecast of $183.00.

The average price target represents a 17.13% change from the last price of $161.02.

Johnson & Johnson Stock Analysis & Ratings

The Johnson & Johnson stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors.

The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Pharmaceutical giant Johnson & Johnson (JNJ) has submitted its latest data to the U.S. Food and Drug Administration (FDA) to gain approval for the use of its COVID-19 booster shot in individuals over 18 years of age. Shares rose on the news and closed at $159.58 on October 5.

A Phase 3 ENSEMBLE 2 study showed that a JNJ booster shot taken 56 days after the primary dose provided 94 percent protection against symptomatic COVID-19 in the U.S. and 100 percent protection against severe COVID-19, 14 days after taking the booster.

JNJ also submitted data from its Phase 1/2a study, which showed that when a JNJ COVID-19 vaccine was taken six months after the initial shot, it increased antibody levels nine-fold one week after the booster and twelve-fold four weeks after the booster. In all, the vaccine was well tolerated when given either as a primary dose or booster.

Commenting on the news, Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson, said, “We look forward to our discussions with the FDA and other health authorities to support their decisions regarding boosters… At the same time, we continue to recognize that a single-shot COVID-19 vaccine that provides strong and long-lasting protection remains a crucial component to vaccinating the global population.”

Last month the company submitted data proving that its single-dose COVID-19 vaccine was 79% effective for COVID-19-related infections and 81% effective for COVID-19 related hospitalizations. Furthermore, the study also proved that vaccine efficacy did not decrease over the period of study from March to July 31, 2021. Comparable vaccine efficacy was witnessed when the study was extended to August 31, 2021, when the Delta variant became dominant in the U.S.

I am neutral on Johnson & Johnson (JNJ), as its stock price looks neither particularly attractive nor expensive at the moment.

Johnson and Johnson is one of the world’s largest healthcare companies, and is commonly referred to as a global healthcare giant because of its consumer health products, medical devices, and pharmaceutical products.

Founded back in 1886 by three brothers, Robert, James, and Edward Johnson, the company has over 135,000 employees across the world today.

Thanks to its broad product diversification, strong and proven research and development team, and robust free cash flow generation working in tandem with its fortress balance sheet, Johnson and Johnson is positioned as a leader in its sector.

It owns significant intellectual property rights that give it strong brands, loyal customers, and the ability to drive excess returns on invested capital across cycles. It is also able to leverage its immense scale to improve efficiencies, and invest vast sums of resources into its R&D pipeline without eating significantly into its profit margins. This should enable it to sustain its competitive advantage for years to come.

Johnson and Johnson recently reported Q2 results. Its overall financial results showed an impressive year-over-year sales growth of 27.7% to $23.3 billion in the second quarter of 2021, with an operational growth of 23% and an adjusted operational growth of 23.8%. EPS increased 72.8% to $2.35, while the adjusted EPS of $2.48 increased 48.5%.

Johnson and Johnson’s chairman and CEO stated that the company’s strong headline growth was driven by the impressive sales and earnings growth across its Medical Device, Consumer Health and Pharmaceutical businesses.

Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, increased 10%. Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 14.1%, driven by STELARA (ustekinumab).

Medical Device worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 58.7%, primarily driven by the benefit of market recovery from COVID-19 impacts, and the associated deferral of medical procedures in the prior year.

Valuation Metrics

Johnson and Johnson’s stock price looks fairly valued at the moment based on EV/EBITDA, which currently stands at 12.3x.

The price-to-normalized earnings ratio of 16.2x is also very close to its five-year average of 16.82x.

Wall Street’s Take

From Wall Street analysts, Johnson and Johnson earns a Moderate Buy analyst consensus, based on four Buy ratings, two Hold ratings, and 0 Sell ratings in the past three months.

Summary and Conclusions

Johnson and Johnson’s stock is not particularly attractively priced, nor is it particularly expensive right now.

The company’s well-diversified healthcare business model and drug portfolio give it strong cash flow stability, and make it a great dividend growth stock.

Add new comment

Order

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.